Literature DB >> 19780981

Alzheimer's disease: report of two autopsy cases with a clinical diagnosis of corticobasal degeneration.

Kenichi Okazaki1, Yong-Juan Fu, Yasushi Nishihira, Minoru Endo, Takao Fukushima, Takeshi Ikeuchi, Kouichirou Okamoto, Osamu Onodera, Masatoyo Nishizawa, Hitoshi Takahashi.   

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. Corticobasal degeneration (CBD) is a rare neurodegenerative disease affecting adults, being characterized clinically by a combination of extrapyramidal signs and focal cortical syndromes. In both diseases, tau deposits are a characteristic neuropathological feature. We report two new patients with autopsy-proven AD, in whom clinical diagnoses of CBD were made during life. The ages of the patients at onset were 52 and 67 years, and the disease durations were 9 and 15 years, respectively. At autopsy, both cases exhibited marked cortical atrophy with evident neuronal loss in the convex areas of the frontal and parietal lobes. Immunohistochemically, AT8-positive neurofibrillary tangles (NFTs) and Abeta-positive senile plaques (SPs) were widespread and abundant in the cerebral cortex (Alzheimer pathology stage VI/C of Braak and Braak), leading us to the final pathological diagnosis of AD. No tau lesions suggestive of CBD were observed, and the deep gray matter areas, including the substantia nigra, were unremarkable (exceptionally, only mild neuronal loss was noted in the putamen in case 2). These findings further strengthen the idea that in AD, neurodegeneration with tau and Abeta deposits may begin in the fronto-parietal neocortical areas, which are often preferentially affected in CBD, earlier than, or as early as the medial temporal lobe, and that extrapyramidal signs, such as rigidity and tremor, can occur in the absence of neuronal loss in the basal ganglia and substantia nigra.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19780981     DOI: 10.1111/j.1440-1789.2009.01062.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  4 in total

Review 1.  The corticobasal syndrome-Alzheimer's disease conundrum.

Authors:  Anhar Hassan; Jennifer L Whitwell; Keith A Josephs
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

2.  In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.

Authors:  Akio Kikuchi; Nobuyuki Okamura; Takafumi Hasegawa; Ryuichi Harada; Shoichi Watanuki; Yoshihito Funaki; Kotaro Hiraoka; Toru Baba; Naoto Sugeno; Ryuji Oshima; Shun Yoshida; Junpei Kobayashi; Michinori Ezura; Michiko Kobayashi; Ohito Tano; Shunji Mugikura; Ren Iwata; Aiko Ishiki; Katsutoshi Furukawa; Hiroyuki Arai; Shozo Furumoto; Manabu Tashiro; Kazuhiko Yanai; Yukitsuka Kudo; Atsushi Takeda; Masashi Aoki
Journal:  Neurology       Date:  2016-10-28       Impact factor: 9.910

Review 3.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

4.  Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome.

Authors:  Nobutaka Sakae; Keith A Josephs; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Jay van Gerpen; Neil R Graff-Radford; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-08-06       Impact factor: 16.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.